Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

M.S. Freedman; C. Metzig; L. Kappos; C.H. Polman; G. Edan; H.P. Hartung; D. H. Miller; X. Montalban; J. Yarden; L. Spector; E. Fire; N. Dotan; S. Schwenke; V. Lanius; R. Sandbrink; C. Pohl

doi:10.1177/1352458511432327

Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

M.S. Freedman, C. Metzig, L. Kappos, C.H. Polman, G. Edan, H.P. Hartung, D. H. Miller, X. Montalban, J. Yarden, L. Spector, E. Fire, N. Dotan, S. Schwenke, V. Lanius, R. Sandbrink, C. Pohl

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	966-973
Journal	Multiple Sclerosis
Volume	18
Issue number	7
DOIs	https://doi.org/10.1177/1352458511432327
Publication status	Published - 2012

Access to Document

10.1177/1352458511432327

Cite this

Freedman, M. S., Metzig, C., Kappos, L., Polman, C. H., Edan, G., Hartung, H. P., ... Pohl, C. (2012). Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. Multiple Sclerosis, 18(7), 966-973. https://doi.org/10.1177/1352458511432327

Freedman, M.S. ; Metzig, C. ; Kappos, L. ; Polman, C.H. ; Edan, G. ; Hartung, H.P. ; Miller, D. H. ; Montalban, X. ; Yarden, J. ; Spector, L. ; Fire, E. ; Dotan, N. ; Schwenke, S. ; Lanius, V. ; Sandbrink, R. ; Pohl, C. / Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. In: Multiple Sclerosis. 2012 ; Vol. 18, No. 7. pp. 966-973.

@article{bdce09e796854b549209b2c54797d207,

title = "Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis",

author = "M.S. Freedman and C. Metzig and L. Kappos and C.H. Polman and G. Edan and H.P. Hartung and Miller, {D. H.} and X. Montalban and J. Yarden and L. Spector and E. Fire and N. Dotan and S. Schwenke and V. Lanius and R. Sandbrink and C. Pohl",

year = "2012",

doi = "10.1177/1352458511432327",

language = "Undefined/Unknown",

volume = "18",

pages = "966--973",

journal = "Multiple Sclerosis",

issn = "1352-4585",

publisher = "SAGE Publications Ltd",

number = "7",

}

Freedman, MS, Metzig, C, Kappos, L, Polman, CH, Edan, G, Hartung, HP, Miller, DH, Montalban, X, Yarden, J, Spector, L, Fire, E, Dotan, N, Schwenke, S, Lanius, V, Sandbrink, R & Pohl, C 2012, 'Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis', Multiple Sclerosis, vol. 18, no. 7, pp. 966-973. https://doi.org/10.1177/1352458511432327

Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis. / Freedman, M.S.; Metzig, C.; Kappos, L.; Polman, C.H.; Edan, G.; Hartung, H.P.; Miller, D. H.; Montalban, X.; Yarden, J.; Spector, L.; Fire, E.; Dotan, N.; Schwenke, S.; Lanius, V.; Sandbrink, R.; Pohl, C.

In: Multiple Sclerosis, Vol. 18, No. 7, 2012, p. 966-973.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Predictive nature of IgM anti-alpha-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

AU - Freedman, M.S.

AU - Metzig, C.

AU - Kappos, L.

AU - Polman, C.H.

AU - Edan, G.

AU - Hartung, H.P.

AU - Miller, D. H.

AU - Montalban, X.

AU - Yarden, J.

AU - Spector, L.

AU - Fire, E.

AU - Dotan, N.

AU - Schwenke, S.

AU - Lanius, V.

AU - Sandbrink, R.

AU - Pohl, C.

PY - 2012

Y1 - 2012

U2 - 10.1177/1352458511432327

DO - 10.1177/1352458511432327

M3 - Article

C2 - 22183938

VL - 18

SP - 966

EP - 973

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 7

ER -